Barclays PLC Increases Holdings in Replimune Group, Inc. (NASDAQ:REPL)

Barclays PLC raised its stake in Replimune Group, Inc. (NASDAQ:REPL) by 165.5% during the third quarter, HoldingsChannel reports. The fund owned 158,491 shares of the company’s stock after buying an additional 98,791 shares during the period. Barclays PLC’s holdings in Replimune Group were worth $1,738,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of New York Mellon Corp boosted its stake in Replimune Group by 10.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 180,226 shares of the company’s stock worth $1,622,000 after purchasing an additional 17,471 shares in the last quarter. Rhumbline Advisers raised its holdings in Replimune Group by 7.2% in the second quarter. Rhumbline Advisers now owns 84,923 shares of the company’s stock worth $764,000 after buying an additional 5,732 shares during the last quarter. TD Asset Management Inc raised its holdings in Replimune Group by 4.6% in the second quarter. TD Asset Management Inc now owns 249,940 shares of the company’s stock worth $2,249,000 after buying an additional 11,094 shares during the last quarter. Arizona State Retirement System bought a new position in shares of Replimune Group in the second quarter worth approximately $108,000. Finally, Los Angeles Capital Management LLC grew its holdings in shares of Replimune Group by 8.1% during the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock valued at $646,000 after buying an additional 5,410 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the sale, the chief executive officer now directly owns 202,014 shares in the company, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares in the company, valued at $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Replimune Group Price Performance

NASDAQ REPL opened at $11.06 on Friday. The stock has a market capitalization of $756.69 million, a price-to-earnings ratio of -3.63 and a beta of 1.28. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $17.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The business’s fifty day moving average price is $12.39 and its 200-day moving average price is $11.13.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. On average, equities analysts predict that Replimune Group, Inc. will post -2.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. BMO Capital Markets boosted their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday, November 22nd. HC Wainwright restated a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a research note on Friday, November 22nd. Jefferies Financial Group upped their price target on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. Finally, JPMorgan Chase & Co. lifted their price objective on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $17.29.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.